At 6 months , survival free from death or urgent left ventricular device implantation was 80 % in the levosimendan , 48 % in the dobutamine ( P = 0.037 versus levosimendan ) , and 43 % in the levosimendan + dobutamine ( P = 0.009 versus levosimendan ) group .
